CUL1 Antibody

Shipped with Ice Packs
In Stock

Description

CUL1 Antibody: Definition and Core Functions

CUL1 antibodies target the Cullin-1 protein, which serves as a scaffold in the SCF E3 ubiquitin ligase complex. This complex mediates substrate-specific ubiquitination, marking proteins for proteasomal degradation . Key roles include:

  • Ubiquitination catalysis: Positions substrates (e.g., cell cycle regulators like cyclin E) and ubiquitin-conjugating enzymes for efficient ubiquitin transfer .

  • Neddylation dependency: CUL1 requires neddylation (covalent modification by NEDD8) for SCF complex activation .

  • Structural organization: Binds SKP1-F-box proteins at its N-terminus and RBX1/ROC1 at its C-terminus to form a functional E3 ligase .

Key Applications in Research

CUL1 antibodies are widely used in techniques such as:

ApplicationDetailsSources
Western Blot (WB)Detects CUL1 at ~90 kDa in HeLa, MCF7, A549, and NIH/3T3 cell lysates .Abcam, Proteintech
Immunoprecipitation (IP)Identifies CUL1 interactions (e.g., with SKP1, RBX1, and Dvl2) .Santa Cruz, CST
Immunohistochemistry (IHC)Localizes CUL1 in human tissues (e.g., placental villi, ovarian carcinoma) .Abcam, Proteintech
Flow CytometryQuantifies intracellular CUL1 levels in permeabilized HeLa cells .Abcam

Role in Trophoblast Invasion

  • Mechanism: CUL1 promotes invasion/migration of trophoblast cells (HTR8/SVneo) by modulating MMP-9/TIMP balance .

  • Clinical relevance: Reduced CUL1 levels in pre-eclamptic placentas correlate with impaired trophoblast function .

Primary Ciliogenesis Regulation

  • Interaction: Binds and ubiquitinates Dishevelled 2 (Dvl2), facilitating its degradation to promote cilia formation .

  • Neddylation requirement: Centrosomal CUL1 activity depends on neddylation for Dvl2 regulation .

Proteasomal Association

  • Binding domain: The N-terminal region (aa 1–300) of CUL1 interacts with 20S proteasome α subunits .

  • Ubiquitylation role: Polyubiquitylation of CUL1 enhances proteasomal binding but does not affect its stability .

Molecular Weight and Validation

  • Predicted: 90 kDa .

  • Observed: 80–90 kDa (variations due to post-translational modifications) .

Therapeutic and Disease Relevance

  • Pre-eclampsia: Downregulated CUL1 in placental villi disrupts trophoblast invasion .

  • Cancer: SCF-CUL1 complexes target oncoproteins (e.g., β-catenin) for degradation, suggesting therapeutic potential .

  • Ciliopathies: Impaired CUL1-Dvl2 interaction may contribute to ciliary dysfunction .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
CUL1 antibody; At4g02570 antibody; T10P11.26Cullin-1 antibody
Target Names
Uniprot No.

Target Background

Function
CUL1 is a protein involved in ubiquitination and subsequent proteasomal degradation of target proteins. It acts as a regulator of mitotic processes, playing a crucial role during gametogenesis and embryogenesis. In conjunction with SKP1, RBX1, and an F-box protein, CUL1 forms a SCF complex. The functional specificity of this complex is determined by the type of F-box protein present. SCF(UFO) is implicated in floral organ development. SCF(TIR1) is involved in the auxin signaling pathway. SCF(COI1) regulates responses to jasmonates. SCF(EID1) and SCF(AFR) are implicated in phytochrome A light signaling. SCF(ADO1/ZTL), SCF(ADO2/LKP2), SCF(ADO3/FKF1) are related to the circadian clock. SCF(ORE9) appears to be involved in senescence. SCF(EBF1/EBF2) may regulate ethylene signaling.
Gene References Into Functions
  1. ALF4 interacts with RBX1 and inhibits the activity of SCF(TIR)(1), an E3 ligase responsible for the degradation of the Aux/IAA transcriptional repressors. In vivo, the alf4 mutation destabilizes the CUL1 subunit of the SCF complex. PMID: 29233834
  2. The axr6-101 phenotype is attributed to the E716K substitution in the CUL1 protein, which likely affects its ability to bind to the C-terminal RING domain of RING-box 1 (RBX1). PMID: 26339842
  3. A new viable recessive allele of the Arabidopsis CULLIN1 gene in the non-reference Wassilewskija (Ws-4) accession was identified. PMID: 24955772
  4. icu13 is a novel recessive allele of AUXIN RESISTANT6 (AXR6), encoding CULLIN1, a critical component of the SCF complex. [ICU13] [ncurvata13] PMID: 23319550
  5. Genetic and physiological data provide direct evidence that AtCUL1 is essential for normal JA responses. PMID: 15860010
  6. A viable and fertile weak allele of CUL1, termed cul1-6, is described. PMID: 17158585
  7. CUL1 is required for TOC1 degradation, suggesting that this protein is the functional cullin in the circadian clock. PMID: 18433436
  8. This study reports the first allele of CUL1 that directly affects subunit interactions at the CUL1 C terminus. PMID: 19114460
  9. CUL1-based SCF E3 ligase activity is essential for Della protein degradation. PMID: 19717618

Show More

Hide All

Database Links

KEGG: ath:AT4G02570

STRING: 3702.AT4G02570.1

UniGene: At.24877

Protein Families
Cullin family
Subcellular Location
Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle. Cytoplasm, cytoskeleton, phragmoplast. Note=Mainly nuclear during interphase and preprophase, but also weakly cytoplasmic during interphase. Associated to mitotic spindle during metaphase, and to the phragmoplast during telophase.
Tissue Specificity
Expressed constitutively in roots, seedlings, stems, leaves and flowers.

Q&A

What is CUL1 and what is its biological significance?

CUL1 is a key component of the SCF (Skp1/CUL-1/F-box protein) E3 ubiquitin ligase complex, which is essential for the targeted degradation of specific proteins. This process is vital for regulating the cell cycle, as CUL1 mediates the ubiquitination and subsequent degradation of critical cell cycle regulators such as cyclin D, p21, and cyclin E. By controlling the levels of these proteins, CUL1 ensures proper cell cycle progression and prevents uncontrolled cell proliferation, which is a hallmark of cancer. Additionally, CUL1 interacts with various F-box proteins, such as Skp2, to determine substrate specificity, highlighting its importance in maintaining cellular homeostasis .

What types of CUL1 antibodies are available for research applications?

Several types of CUL1 antibodies are available for different research applications:

  • Monoclonal antibodies: Mouse monoclonal antibodies like CUL-1 Antibody (D-5) that detect CUL1 from multiple species including mouse, rat, and human origin .

  • Polyclonal antibodies: Rabbit polyclonal antibodies like AS23 4927 that target specific regions of CUL1, particularly for plant species like Arabidopsis thaliana .

  • Conjugated antibodies: CUL1 antibodies conjugated to agarose, horseradish peroxidase (HRP), fluorescein isothiocyanate (FITC), phycoerythrin (PE), and Alexa Fluor® conjugates for specialized applications .

These antibodies are validated for multiple applications including western blotting, immunoprecipitation, immunofluorescence, immunohistochemistry, and ELISA .

How do I select the appropriate CUL1 antibody for my specific research application?

When selecting a CUL1 antibody, consider:

  • Species reactivity: Ensure the antibody recognizes CUL1 from your species of interest. Available antibodies react with human, mouse, rat, and Arabidopsis thaliana CUL1, with predicted reactivity to other plant species .

  • Application compatibility: Verify the antibody is validated for your specific application (WB, IP, IF, IHC, or ELISA). For instance, the CUL-1 Antibody (D-5) is validated for multiple applications, while the Arabidopsis-specific antibody (AS23 4927) is validated specifically for Western blotting .

  • Epitope location: Consider whether the epitope might be masked by protein interactions or post-translational modifications. The N-terminal region of CUL1 interacts with proteasome subunits, which might affect antibody accessibility .

  • Clonality: Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies recognize multiple epitopes and may provide stronger signals in certain applications .

What are the optimized protocols for CUL1 immunoprecipitation experiments?

For successful CUL1 immunoprecipitation:

  • Lysis buffer selection: Use buffers that preserve native protein complexes. Research shows that CUL1 interactions with proteasome subunits are preserved in standard IP buffers containing mild detergents .

  • Antibody selection: Choose antibodies specifically validated for IP. The CUL-1 Antibody (D-5) or its agarose-conjugated version (D-5 AC) are suitable options .

  • Co-immunoprecipitation considerations: When studying CUL1 interactions with proteasome subunits, be aware that different subunits may co-precipitate to varying degrees. Research shows Cul1 co-immunoprecipitated with the alpha 6, alpha 2, and alpha 4 subunits, with some Skp1 and Roc1 also present in the alpha 6 immunoprecipitate .

  • Controls: Include appropriate negative controls such as non-specific IgG immunoprecipitation and input samples to validate specificity .

  • Post-translational modifications: Consider that ubiquitylated forms of CUL1 may show different interaction patterns compared to unmodified CUL1. High molecular weight forms of CUL1 (likely ubiquitylated) preferentially bind to S5a subunit of the 19S proteasome .

How can I detect and distinguish between different modified forms of CUL1?

CUL1 undergoes several post-translational modifications that can be detected and distinguished as follows:

  • Molecular weight differences on Western blots:

    • Unmodified CUL1: ~86.3 kDa

    • Neddylated CUL1: Appears as a slightly higher molecular weight band

    • Ubiquitylated CUL1: Multiple higher molecular weight bands

  • Specific manipulations:

    • Use methylated ubiquitin or Ub(K0) mutant (ubiquitin with all lysines mutated to arginines) to inhibit polyubiquitin chain formation. This changes the pattern of CUL1 bands, with lower molecular weight forms binding to GST-S5a .

    • Co-transfection with Ub(K0) mutant in vivo can eliminate high molecular weight species of CUL1 .

  • Validation approaches:

    • Nickel agarose pulldown with His-tagged ubiquitin can confirm ubiquitylated forms of CUL1 .

    • Immunoprecipitation followed by immunoblotting with antibodies specific to ubiquitin or NEDD8 can confirm these modifications.

The research shows that when polyubiquitylation is inhibited by expression of the Ub(K0) mutant, high molecular weight forms of CUL1 no longer bind to GST-S5a, indicating that ubiquitylation of CUL1 in vivo is required for its interaction with the S5a proteasomal subunit .

What are the key considerations for studying CUL1 interactions with proteasome subunits?

Based on published research, consider these key factors:

  • Domain-specific interactions: The N-terminus of CUL1 (amino acids 1-300) is necessary and sufficient for binding to alpha subunits of the 20S proteasome, while ubiquitylated forms of CUL1 interact with the S5a subunit of the 19S proteasome .

  • Modification-dependent interactions: Ubiquitylation status significantly affects CUL1's proteasome interactions. High molecular weight forms of CUL1 preferentially bind to S5a, and this interaction is disrupted when polyubiquitylation is inhibited .

  • Experimental approach selection:

    • For studying direct binding, in vitro translated CUL1 can be used with GST-tagged proteasome subunits .

    • For studying endogenous interactions, co-immunoprecipitation with antibodies to specific proteasome subunits (alpha 6, alpha 2, alpha 4) is effective .

    • For mapping interaction domains, deletion mutants of CUL1 can be expressed and immunoprecipitated .

  • Effect of ubiquitin chain inhibition: Using methylated ubiquitin in vitro or Ub(K0) mutant in vivo changes the binding pattern of CUL1 to proteasomal subunits, particularly affecting interaction with the S5a subunit .

  • Stability considerations: Interestingly, inhibition of polyubiquitylation of CUL1 does not significantly affect the stability of CUL1, unlike its effect on other proteins like p21 and cyclin E .

Why might I observe multiple bands when detecting CUL1 by Western blotting?

Multiple bands when detecting CUL1 by Western blotting can be attributed to:

  • Post-translational modifications:

    • Neddylation adds approximately 8 kDa, resulting in a band at ~94-98 kDa

    • Ubiquitylation creates multiple higher molecular weight bands

    • Research shows that CUL1 can be found in high molecular weight forms corresponding to ubiquitylated CUL1

  • Degradation products: Incomplete protease inhibition during sample preparation may lead to CUL1 degradation fragments.

  • Alternative splicing: Different isoforms of CUL1 may exist in certain tissues or species.

  • Cross-reactivity: Some antibodies may cross-react with other cullin family members (CUL2-5) that share structural similarities with CUL1.

  • Experimental manipulation effects:

    • Expression of Ub(K0) mutant can eliminate high molecular weight species which would otherwise appear in Western blots

    • These high molecular weight species can be specifically purified using nickel agarose pulldown when co-expressed with His-tagged ubiquitin

When interpreting multiple bands, consider using specific controls such as lysates from cells expressing CUL1 deletion mutants or cells treated with inhibitors of specific modifications to help identify the nature of each band .

What factors might affect the success of co-immunoprecipitation experiments with CUL1?

Several factors can impact CUL1 co-immunoprecipitation success:

  • CUL1 modification state:

    • The ubiquitylation state of CUL1 significantly affects its binding partners, especially proteasome subunits

    • Inhibition of polyubiquitylation changes CUL1's interaction profile

  • Complex integrity:

    • CUL1 functions within SCF complexes; disruption of these complexes may affect co-immunoprecipitation results

    • Research shows that Cul1, but not always Skp1, Roc1 or Skp2, co-precipitates with proteasome subunits under certain conditions

  • Antibody selection:

    • Different antibodies may recognize different epitopes that could be masked in certain protein complexes

    • Epitope accessibility may be affected by CUL1's incorporation into larger complexes

  • Lysis and washing conditions:

    • Overly stringent conditions may disrupt protein-protein interactions

    • Insufficient washing may lead to non-specific binding and false positives

  • Interaction dynamics:

    • Some interactions may be transient or context-dependent

    • Cell cycle stage can affect CUL1's interaction profile

Research demonstrates that while some interactions (like CUL1 with alpha subunits) are relatively stable, others (like interaction with S5a through ubiquitylation) are dependent on specific modifications and can be disrupted by experimental manipulations such as expression of Ub(K0) mutant .

How can I confirm the specificity of CUL1 antibody in my experimental system?

To confirm CUL1 antibody specificity:

  • Knockdown/knockout validation:

    • Perform siRNA knockdown or CRISPR/Cas9 knockout of CUL1

    • The specific band should be reduced or absent in Western blots

  • Overexpression controls:

    • Overexpress tagged CUL1 (e.g., HA-tagged as used in research)

    • Confirm co-detection with both anti-tag and anti-CUL1 antibodies

  • Peptide competition assay:

    • Pre-incubate the antibody with the immunizing peptide

    • This should block specific binding and eliminate the true CUL1 signal

  • Cross-species validation:

    • Test the antibody on samples from different species based on the claimed reactivity

    • CUL1 antibodies have been validated for detection of mouse, rat, human, and Arabidopsis thaliana CUL1

  • Application-specific controls:

    • For immunoprecipitation: Compare with non-specific IgG

    • For immunofluorescence: Include secondary-only controls and pre-immune serum controls

  • Molecular weight verification:

    • Confirm that the detected band matches the expected molecular weight (approximately 86.3 kDa for unmodified CUL1)

    • Higher molecular weight forms correspond to modified CUL1

How can I investigate the dynamic relationship between CUL1 neddylation and ubiquitylation?

To study the dynamic relationship between CUL1 modifications:

  • Time-course experiments:

    • Synchronize cells and analyze CUL1 modifications throughout the cell cycle

    • Use cycloheximide chase assays to determine the half-life of differently modified CUL1 forms

    • Research has used half-life experiments to analyze CUL1 stability under different conditions

  • Inhibitor studies:

    • Use MLN4924 to inhibit neddylation

    • Apply proteasome inhibitors to assess the fate of ubiquitylated CUL1

    • Employ the Ub(K0) mutant to inhibit polyubiquitylation and assess effects on CUL1

  • In vitro reconstitution:

    • Perform in vitro ubiquitylation assays with recombinant components

    • Use methylated ubiquitin to manipulate ubiquitin chain formation

    • Test how neddylation affects subsequent ubiquitylation and vice versa

  • Quantitative proteomics:

    • Use mass spectrometry to identify and quantify modification sites

    • Employ SILAC or TMT labeling to compare modification patterns under different conditions

  • Mutation analysis:

    • Create CUL1 mutants lacking specific modification sites

    • Analyze how these mutations affect subsequent modifications and protein interactions

Research has demonstrated that inhibition of polyubiquitin chain formation (using Ub(K0) mutant) affects CUL1's ability to interact with the S5a subunit without significantly affecting CUL1 stability, suggesting complex regulatory relationships between these modifications .

What approaches can be used to study CUL1's role in proteasomal targeting of substrates?

To investigate CUL1's role in proteasomal targeting:

  • Substrate identification and validation:

    • Immunoprecipitate CUL1 and identify associated substrates by mass spectrometry

    • Confirm direct ubiquitylation of substrates using in vitro ubiquitylation assays

    • Verify substrate degradation depends on CUL1 using knockdown/knockout approaches

  • Domain mapping:

    • Research has shown that the N-terminus of CUL1 (amino acids 1-300) binds to alpha subunits of the 20S proteasome

    • Create and analyze deletion mutants to map domains involved in substrate recognition versus proteasome binding

    • Test how these different domains contribute to substrate degradation kinetics

  • Manipulation of CUL1-proteasome interactions:

    • Express the N-terminal fragment of CUL1 as a dominant negative to disrupt proteasome binding

    • Test how disrupting specific interactions affects substrate degradation

    • Analyze whether CUL1's interaction with alpha subunits is required for substrate degradation

  • Visualization approaches:

    • Use fluorescently tagged CUL1 and substrates to track localization during degradation

    • Apply proximity ligation assays to visualize CUL1-substrate-proteasome ternary complexes in situ

  • Analysis of modification-dependent interactions:

    • Research shows that ubiquitylated forms of CUL1 bind the S5a subunit of the 19S proteasome

    • Investigate whether this interaction facilitates the recruitment of SCF substrates to the proteasome

    • Test the hypothesis that CUL1 ubiquitylation might serve as an additional mechanism for delivery of ubiquitylated substrates to the proteasome

How can I distinguish between SCF-dependent and SCF-independent functions of CUL1?

To differentiate between SCF-dependent and SCF-independent functions:

  • Component-selective perturbation:

    • Knockdown/knockout of specific SCF components (Skp1, specific F-box proteins)

    • Research shows that Cul1, but not always Skp1, Roc1 or Skp2, co-precipitates with proteasome subunits under certain conditions

    • Analyze which CUL1 functions persist in the absence of other SCF components

  • Domain-specific analysis:

    • The N-terminus of CUL1 (aa 1-300) is necessary and sufficient for binding to 20S proteasome alpha subunits

    • Express CUL1 mutants with disrupted domains for either SCF formation or proteasome binding

    • Assess which functions are affected by specific domain mutations

  • Interaction proteomics:

    • Compare CUL1 interactome with interactomes of other SCF components

    • Identify proteins that interact exclusively with CUL1 but not with other SCF subunits

    • Verify these interactions using co-immunoprecipitation and functional assays

  • Substrate profiling:

    • Compare ubiquitylation patterns in cells with CUL1 knockdown versus knockdown of other SCF components

    • Identify substrates whose ubiquitylation depends specifically on CUL1 but not on the intact SCF complex

  • Localization studies:

    • Use immunofluorescence to identify cellular locations where CUL1 is present but other SCF components are absent

    • Analyze the functional significance of these distinct localization patterns

The research evidence suggests the existence of SCF-independent functions, as CUL1 interacts with proteasomal subunits in ways that don't always involve other SCF components .

What is known about the role of CUL1 in neurodegenerative diseases and how can antibody-based techniques help investigate this?

While the provided search results don't directly address CUL1 in neurodegenerative diseases, we can outline approaches based on known CUL1 functions:

  • Protein aggregation studies:

    • CUL1 is part of the ubiquitin-proteasome system critical for protein quality control

    • Use CUL1 antibodies for immunohistochemistry to examine co-localization with disease-associated protein aggregates in brain tissues

    • Investigate whether CUL1 function is altered in the presence of protein aggregates

  • Post-mortem tissue analysis:

    • Compare CUL1 levels, localization, and modification states in brain tissues from patients versus controls

    • Analyze whether CUL1-proteasome interactions are altered in disease states

  • Disease models:

    • Study CUL1 function in cellular and animal models of neurodegenerative diseases

    • Use antibodies to track CUL1 dynamics during disease progression

  • Substrate identification:

    • Identify neurodegeneration-specific CUL1 substrates through immunoprecipitation and proteomics

    • Determine if disease-associated proteins are targeted by CUL1-containing complexes

  • Therapeutic targeting:

    • Develop approaches to modulate CUL1 activity in disease contexts

    • Use antibodies as tools to validate target engagement in preclinical studies

How can recent advances in proximity labeling be applied to study CUL1 interaction networks?

Proximity labeling techniques can be powerful tools for studying CUL1 networks:

  • BioID or TurboID approaches:

    • Fuse biotin ligase to CUL1 to biotinylate proteins in close proximity

    • Compare proximity interactomes of wild-type CUL1 versus mutants lacking specific domains (e.g., the N-terminal region that binds proteasome alpha subunits)

    • Identify differences in the interactome when polyubiquitylation is inhibited using Ub(K0)

  • APEX2 labeling:

    • Use APEX2-CUL1 fusions for rapid proximity labeling with temporal control

    • Perform time-course experiments to capture dynamic interaction changes during cell cycle progression

  • Split-BioID systems:

    • Apply split-BioID between CUL1 and potential interactors

    • Investigate specific interaction interfaces such as those between CUL1 and proteasome subunits

  • Compartment-specific analysis:

    • Target BioID-CUL1 to specific cellular compartments

    • Determine compartment-specific interaction networks

  • Validation with traditional approaches:

    • Confirm proximity labeling results using co-immunoprecipitation with CUL1 antibodies

    • Perform reciprocal labeling experiments using proteasome subunits as baits

  • Quantitative analysis of modification-dependent interactions:

    • Compare interactomes of unmodified versus ubiquitylated CUL1

    • Research shows that ubiquitylation status affects CUL1's interaction with the S5a subunit

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.